Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean umeclidinium bromide and vilanterol trifenatate and fluticasone furoate?
Displaying drugs 13751 - 13775 of 14602 in total

Cimicoxib

Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …

LG-100268

LG-100268 is a retinoid X receptor (RXR) selective compound.
Experimental

5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine

Experimental

1h-Benoximidazole-2-Carboxylic Acid

Experimental

7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide

Experimental

2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium

Experimental

4,5,6,7-Tetrachloro-3h-Isobenzofuran-1-One

Experimental

SB220025

Experimental

1-Naphthyl-L-alanine

Experimental

3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine

Experimental

3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL

Experimental

2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE

Experimental

CERC-301

Mk 0657 has been used in trials studying the treatment of Major Depressive Disorder.
Investigational

MK-6186

MK6186 has been used in trials studying the treatment of HIV-1 Infection.
Investigational

Ethadione

Experimental

ABH001

ABH001 is under investigation in clinical trial NCT01749306 (A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing).
Investigational
Matched Description: … ABH001 is under investigation in clinical trial NCT01749306 (A Study of the Efficacy and Safety of ABH001 …

Molibresib

Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
Investigational
Matched Description: … NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and …

NM-702

Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. ... Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and …

[4,6-O-(1-CARBOXYETHYLIDENE)-BETA-D-MANNOSE]

Experimental

(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE

Experimental

[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID

Experimental

5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

Experimental

N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine

Experimental

4-(1H-IMIDAZOL-1-YL)PHENOL

Experimental

(5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE

Experimental
Displaying drugs 13751 - 13775 of 14602 in total